Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents
نویسندگان
چکیده
Nikolova, Soni S. Pullamsetti, Norbert Weissmann, Eva Dony, Rajkumar Savai, Hossein A. Martina Klein, Ralph T. Schermuly, Peter Ellinghaus, Hendrik Milting, Bernd Riedl, Sevdalina Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2008 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.108.779751 2008;118:2081-2090; originally published online October 27, 2008; Circulation. http://circ.ahajournals.org/content/118/20/2081 World Wide Web at: The online version of this article, along with updated information and services, is located on the
منابع مشابه
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
BACKGROUND Inhibition of tyrosine kinases, including platelet-derived growth factor receptor, can reduce pulmonary arterial pressure in experimental and clinical pulmonary hypertension. We hypothesized that inhibition of the serine/threonine kinases Raf-1 (also termed c-Raf) and b-Raf in addition to inhibition of tyrosine kinases effectively controls pulmonary vascular and right heart remodelin...
متن کاملDiscovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Traditional medicines have become the most productive source of leads for drugs development, particularly as anti-cancer agents. Various screening approaches are being applied. Sorafenib, a multikinase inhibitor, is used to treat primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer. A small library of compounds analogous to sorafenib were designed and screened...
متن کاملPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Although patients with advanced refractory solid tumors have poor prognosis, the clinical development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers. In vivo and in vitro studies have shown that the oral multikinase inhibitor, sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapop...
متن کاملExpression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
BACKGROUND Sorafenib, a multitarget kinase inhibitor, inhibits members of the mitogen-activated protein kinase (MAPK) pathway and receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGF-R2). Sorafenib, carboplatin, and paclitaxel (SCP) has antitumor activity in melanoma patients, but no association was found between response and activating B-Raf V600E mutations....
متن کاملAutophagy orchestrates adaptive responses to targeted therapy in endometrial cancer
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-appro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008